Pembrolizumab in Locally Advanced Sinonasal Carcinoma

NCT05925491 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Sinonasal Undifferentiated Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Docetaxel
DRUG: Carboplatin

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Collaborators

[object Object]